| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
HLS Stock Overview
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally.
HLS Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$13.48 |
| 52 Week High | CA$20.52 |
| 52 Week Low | CA$11.98 |
| Beta | 0.76 |
| 1 Month Change | -7.29% |
| 3 Month Change | -4.40% |
| 1 Year Change | -20.19% |
| 3 Year Change | -15.86% |
| 5 Year Change | n/a |
| Change since IPO | 16.31% |
Recent News & Updates
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of September, with...
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of September, with...
Shareholder Returns
| HLS | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | 7.8% | -1.9% | -0.7% |
| 1Y | -20.2% | -25.9% | 5.2% |
Return vs Industry: HLS exceeded the Canadian Healthcare industry which returned -25.2% over the past year.
Return vs Market: HLS underperformed the Canadian Market which returned 4.8% over the past year.
Price Volatility
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 9.0% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in CA Market | 16.9% |
| 10% least volatile stocks in CA Market | 4.3% |
Stable Share Price: HLS is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HLS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 92 | Gilbert Godin | https://www.hlstherapeutics.com |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests.
HLS Therapeutics Fundamentals Summary
| HLS fundamental statistics | |
|---|---|
| Market Cap | US$340.37m |
| Earnings (TTM) | -US$11.98m |
| Revenue (TTM) | US$60.25m |
5.6x
P/S Ratio-28.4x
P/E RatioIs HLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLS income statement (TTM) | |
|---|---|
| Revenue | US$60.25m |
| Cost of Revenue | US$9.77m |
| Gross Profit | US$50.48m |
| Other Expenses | US$62.46m |
| Earnings | -US$11.98m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 83.78% |
| Net Profit Margin | -19.88% |
| Debt/Equity Ratio | 58.7% |
How did HLS perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield-43%
Payout RatioDoes HLS pay a reliable dividends?
See HLS dividend history and benchmarks| HLS Therapeutics dividend dates | |
|---|---|
| Ex Dividend Date | Jul 28 2022 |
| Dividend Pay Date | Sep 15 2022 |
| Days until Ex dividend | 63 days |
| Days until Dividend pay date | 112 days |
Does HLS pay a reliable dividends?
See HLS dividend history and benchmarksValuation
Is HLS Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HLS (CA$13.48) is trading below our estimate of fair value (CA$104.02)
Significantly Below Fair Value: HLS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HLS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Canadian Healthcare industry average.
PE vs Market: HLS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HLS is overvalued based on its Price-To-Book Ratio (2.1x) compared to the CA Healthcare industry average (2x).
Future Growth
How is HLS Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
60.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: HLS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HLS's is expected to become profitable in the next 3 years.
Revenue vs Market: HLS's revenue (35.1% per year) is forecast to grow faster than the Canadian market (6.4% per year).
High Growth Revenue: HLS's revenue (35.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HLS's Return on Equity is forecast to be high in 3 years time
Past Performance
How has HLS Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-4.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLS is currently unprofitable.
Growing Profit Margin: HLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HLS is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare HLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-38.1%).
Return on Equity
High ROE: HLS has a negative Return on Equity (-7.53%), as it is currently unprofitable.
Financial Health
How is HLS Therapeutics's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HLS's short term assets ($43.9M) exceed its short term liabilities ($26.4M).
Long Term Liabilities: HLS's short term assets ($43.9M) do not cover its long term liabilities ($85.1M).
Debt to Equity History and Analysis
Debt Level: HLS's net debt to equity ratio (44.4%) is considered high.
Reducing Debt: HLS's debt to equity ratio has reduced from 81.2% to 58.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HLS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HLS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 35.2% per year.
Dividend
What is HLS Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
1.47%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: HLS's dividend (1.47%) isn’t notable compared to the bottom 25% of dividend payers in the Canadian market (1.9%).
High Dividend: HLS's dividend (1.47%) is low compared to the top 25% of dividend payers in the Canadian market (4.91%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, HLS has been paying a dividend for less than 10 years.
Growing Dividend: HLS's dividend payments have increased, but the company has only paid a dividend for 4 years.
Earnings Payout to Shareholders
Earnings Coverage: HLS is paying a dividend but the company is unprofitable.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (42.2%), HLS's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average management tenure
CEO
Gilbert Godin (62 yo)
1.58yrs
Tenure
US$1,351,402
Compensation
Mr. Gilbert Godin Co-founded HLS Therapeutics Inc. in 2014 and has been its Chief Executive Officer and Director since October 1, 2020. Mr. Godin served as President and Chief Operating Officer at HLS Ther...
CEO Compensation Analysis
Compensation vs Market: Gilbert's total compensation ($USD1.35M) is above average for companies of similar size in the Canadian market ($USD982.51K).
Compensation vs Earnings: Gilbert's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: HLS's management team is considered experienced (3.7 years average tenure).
Board Members
Experienced Board: HLS's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HLS insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
HLS Therapeutics Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: HLS Therapeutics Inc.
- Ticker: HLS
- Exchange: TSX
- Founded: 2018
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: CA$437.673m
- Shares outstanding: 32.47m
- Website: https://www.hlstherapeutics.com
Number of Employees
Location
- HLS Therapeutics Inc.
- 10 Carlson Court
- Suite 701
- Etobicoke
- Ontario
- M9W 6L2
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/24 00:00 |
| End of Day Share Price | 2022/05/24 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.